Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8F0L

Crystal Structure of the Human T cell Receptor CD3(EPSILON) N-Terminal Peptide Complexed with ADI-26906 FAB

8F0L の概要
エントリーDOI10.2210/pdb8f0l/pdb
分子名称ADI-26906 Fab Heavy Chain, ADI-26906 Fab Light Chain, T-cell surface glycoprotein CD3 epsilon chain, ... (5 entities in total)
機能のキーワードcd3 epsilon, antibody-antigen complex, membrane protein-immune system complex, immune system
由来する生物種Homo sapiens
詳細
タンパク質・核酸の鎖数6
化学式量合計99683.03
構造登録者
Battles, M.B.,Welin, M. (登録日: 2022-11-03, 公開日: 2023-03-29, 最終更新日: 2024-10-16)
主引用文献Liu, C.Y.,Ahonen, C.L.,Brown, M.E.,Zhou, L.,Welin, M.,Krauland, E.M.,Pejchal, R.,Widboom, P.F.,Battles, M.B.
Structure-based engineering of a novel CD3 epsilon-targeting antibody for reduced polyreactivity.
Mabs, 15:2189974-2189974, 2023
Cited by
PubMed Abstract: Bispecific antibodies continue to represent a growth area for antibody therapeutics, with roughly a third of molecules in clinical development being T-cell engagers that use an anti-CD3 binding arm. CD3 antibodies possessing cross-reactivity with cynomolgus monkey typically recognize a highly electronegative linear epitope at the extreme N-terminus of CD3 epsilon (CD3ε). Such antibodies have high isoelectric points and display problematic polyreactivity (correlated with poor pharmacokinetics for monospecific antibodies). Using insights from the crystal structure of anti-Hu/Cy CD3 antibody ADI-26906 in complex with CD3ε and antibody engineering using a yeast-based platform, we have derived high-affinity CD3 antibody variants with very low polyreactivity and significantly improved biophysical developability. Comparison of these variants with CD3 antibodies in the clinic (as part of bi- or multi-specifics) shows that affinity for CD3 is correlated with polyreactivity. Our engineered CD3 antibodies break this correlation, forming a broad affinity range with no to low polyreactivity. Such antibodies will enable bispecifics with improved pharmacokinetic and safety profiles and suggest engineering solutions that will benefit the large and growing sector of T-cell engagers.
PubMed: 36991534
DOI: 10.1080/19420862.2023.2189974
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.81 Å)
構造検証レポート
Validation report summary of 8f0l
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon